<?xml version="1.0" ?>
<document id="6a246d3621609eba5e7fb36c483280aa9cacd166">
  <chunk id="6a246d3621609eba5e7fb36c483280aa9cacd166.c0" text="Vesicular Stomatitis Virus-Vectored Multi-Antigen Tuberculosis Vaccine Limits Bacterial Proliferation in Mice following a Single Intranasal Dose">
    <entity charOffset="10-20" id="6a246d3621609eba5e7fb36c483280aa9cacd166.c0.e0" ontology_id="DOID_9637" text="Stomatitis" type="disease"/>
    <entity charOffset="50-62" id="6a246d3621609eba5e7fb36c483280aa9cacd166.c0.e1" ontology_id="DOID_399" text="Tuberculosis" type="disease"/>
  </chunk>
  <chunk id="6a246d3621609eba5e7fb36c483280aa9cacd166.c1" text="Tuberculosis (TB) remains a serious health problem worldwide, and an urgent need exists to improve or replace the available vaccine, Mycobacterium bovis bacillus Calmette-Guérin (BCG). Most vaccination protocols adapt two or three doses to induce long-term lasting immunity. Our previous study showed that the naked DNA encoding the triple-antigen fusion TFP846 (Rv3615c-Mtb10.4-Rv2660c) induced robust T cellular immune responses accompanying four inoculations against mycobacteria infection. However, a number of compliance issues exist in some areas lacking the appropriate medical infrastructure with multiple administrations. In this study, a novel vesicular stomatitis virus expressing TFP846 (VSV-846) was developed and the immune responses elicited by VSV-846 were evaluated. We observed that intranasal delivery of VSV-846 induced a potent antigen-specific T cell response following a single dose and VSV-846 efficiently controlled bacterial growth to levels ∼10-fold lower than that observed in the mock group 6 weeks post-infection in BCG-infected mice. Importantly, mice immunized with VSV-846 provided long-term protection against mycobacteria infection compared with those receiving p846 or BCG immunization. Increased memory T cells were also observed in the spleens of VSV-846-vaccinated mice, which could be a potential mechanism associated with long-term protective immune response. These findings supported the use of VSV as an antigen delivery vector with the potential for TB vaccine development.">
    <entity charOffset="0-12" id="6a246d3621609eba5e7fb36c483280aa9cacd166.c1.e0" ontology_id="DOID_399" text="Tuberculosis" type="disease"/>
    <entity charOffset="316-319" id="6a246d3621609eba5e7fb36c483280aa9cacd166.c1.e1" ontology_id="CHEBI_16991" text="DNA" type="chemical"/>
    <entity charOffset="664-674" id="6a246d3621609eba5e7fb36c483280aa9cacd166.c1.e2" ontology_id="DOID_9637" text="stomatitis" type="disease"/>
    <entity charOffset="1205-1208" id="6a246d3621609eba5e7fb36c483280aa9cacd166.c1.e3" ontology_id="CHEBI_41001" text="BCG" type="chemical"/>
    <entity charOffset="1447-1454" id="6a246d3621609eba5e7fb36c483280aa9cacd166.c1.e4" ontology_id="CHEBI_59132" text="antigen" type="chemical"/>
    <pair e1="6a246d3621609eba5e7fb36c483280aa9cacd166.c1.e0" e2="6a246d3621609eba5e7fb36c483280aa9cacd166.c1.e1" id="6a246d3621609eba5e7fb36c483280aa9cacd166.c1.p0" relation="true"/>
    <pair e1="6a246d3621609eba5e7fb36c483280aa9cacd166.c1.e0" e2="6a246d3621609eba5e7fb36c483280aa9cacd166.c1.e3" id="6a246d3621609eba5e7fb36c483280aa9cacd166.c1.p1" relation="true"/>
    <pair e1="6a246d3621609eba5e7fb36c483280aa9cacd166.c1.e0" e2="6a246d3621609eba5e7fb36c483280aa9cacd166.c1.e4" id="6a246d3621609eba5e7fb36c483280aa9cacd166.c1.p2" relation="true"/>
    <pair e1="6a246d3621609eba5e7fb36c483280aa9cacd166.c1.e1" e2="6a246d3621609eba5e7fb36c483280aa9cacd166.c1.e2" id="6a246d3621609eba5e7fb36c483280aa9cacd166.c1.p3" relation="true"/>
    <pair e1="6a246d3621609eba5e7fb36c483280aa9cacd166.c1.e2" e2="6a246d3621609eba5e7fb36c483280aa9cacd166.c1.e3" id="6a246d3621609eba5e7fb36c483280aa9cacd166.c1.p4" relation="true"/>
    <pair e1="6a246d3621609eba5e7fb36c483280aa9cacd166.c1.e2" e2="6a246d3621609eba5e7fb36c483280aa9cacd166.c1.e4" id="6a246d3621609eba5e7fb36c483280aa9cacd166.c1.p5" relation="true"/>
  </chunk>
</document>
